Self-proclaimed ‘boutique CDMO’ STC Biologics has begun initial runs from its newly constructed single-use mammalian plant in Newton, Massachusetts. Contract development and manufacturing organization (CDMO) STC Biologics has undertaken its initial master cell bank (MCB) and three drug substance production runs at its new 3,500 square-foot facility, close to Cambridge, Massachusetts. The plant, which could create up to 30 jobs, brings Good Manufacturing Practice (GMP) manufacturing capabilities to the firm at a 500 L bioreactor scale, expandable to 1,000 L.…